While many cases are treatable, a subset can become highly aggressive, spreading to distant organs and resisting conventional therapies
Pharma giant targets new standards of care
The study is being conducted through its Japan-based pharmaceutical arm, Asahi Kasei Therapeutics Corp
The deal the group says marks a decisive push deeper into severe infectious diseases and the build-out of a global specialty pharmaceuticals platform
Policy symposium in Hyderabad focuses on life skills education and community?driven solutions
The company announced that its Phase III FENhance 1 and 2 studies both met their primary endpoints
The Phase III METEOROID study met its primary endpoint, with ENSPRYNG cutting the risk of a first relapse by 68% compared to placebo in adults and adolescents
The newly formed team is led by Tomabu Adjobimey, an immunologist known for his work in host-pathogen interactions and immune modulation
SBE303 targets Nectin-4, an adhesion protein overexpressed in multiple tumor types, including urothelial, lung, and breast cancers
By prioritising absolute compliance, leveraging the power of digital tools, and aligning with government policies, the sector is locking in its future leadership
Subscribe To Our Newsletter & Stay Updated
